Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Alzheimer’s Disease (AD) Report Overview

In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact cause of AD is not fully understood, scientists evaluated that in most cases the disease is caused by a combination of genetic, lifestyle, and environmental factors that affect the brain over time. Recent research studies and clinical trials are focused on the role of two proteins, beta-amyloid and tau proteins, to identify disease etiology.

Alzheimer’s Disease (AD) Market Outlook, 2023-2033 (Total Prevalent Cases)

Alzheimer’s Disease (AD) Market Outlook, 2023-2033 (Total Prevalent Cases)

Buy the Full Report for More Insights into the Alzheimer’s Disease (AD) Market Forecast

Download a Free Report Sample

The AD market research report provides an overview of the risk factors and the global and historical epidemiological trends impacting the disease in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). Additionally, this report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AD by DSM-IV criteria. The total prevalent cases and the diagnosed prevalent cases of AD are segmented by age (65–69 years, 70–79 years, and 80 years and older) and sex.

Market Size (2023) 15,987,619 Cases
AGR (2023-2033) >4%
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Spain

·       Italy

·       The UK

·       Japan

·       China

Key Sex Segments ·       Men

·       Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Alzheimer’s Disease (AD) Market Segmentation by Country

The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, Japan, and China. In 2023, the US accounted for the highest percentage of total prevalent cases of AD in the 8MM. Any change in the total prevalent cases of AD by DSM-IV criteria is attributable to changing population demographics in the 8MM.

` Alzheimer’s Disease (AD) Market Analysis by Country, 2023 (%)

` Alzheimer’s Disease (AD) Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the Alzheimer’s Disease (AD) Market
Download a Free Report Sample

Alzheimer’s Disease (AD) Market Segmentation by Sex

Based on sex, the market can be segmented into men and women. In 2023, the total prevalent cases of Alzheimer’s disease (AD) in the 8MM were higher in women than men. Among the 8MM, Italy had the largest differences in the total prevalent cases of Alzheimer’s disease (AD) in men and women.

Alzheimer’s Disease (AD) Market Analysis by Sex, 2023 (%)

Alzheimer’s Disease (AD) Market Analysis by Sex, 2023 (%)

Buy the Full Report for More Sex Insights into the Alzheimer’s Disease (AD) Market

Download a Free Report Sample

Segments Covered in the Report

Alzheimer’s Disease (AD) Market Country Outlook (Total Prevalent Cases)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan
  • China

Alzheimer’s Disease (AD) Market Sex Outlook (Total Prevalent Cases)

  • Men
  • Women

Scope of Report

  • The report also includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of MCI segmented by age (65–69 years, 70–79 years, and 80 years and older) and sex.
  • The report provides a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of pre-clinical (pre-symptomatic) AD segmented by age (55–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.
  • The report also includes the total prevalent cases and diagnosed prevalent cases of AD by severity. Although not covered in this report, total prevalent cases and diagnosed prevalent cases of EOAD can be found in the model.
  • This epidemiology forecast for AD is supported by data obtained from peer-reviewed articles and population-based studies. GlobalData epidemiologists applied the DSM-IV criteria to diagnose AD patients across the 8MM. Accordingly, the total prevalent cases and diagnosed prevalent cases of AD in the 8MM are based on the latest data available by DSM-IV criteria. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast total prevalent cases and the diagnosed prevalent cases of AD across these markets.

Reasons to buy

The Alzheimer’s disease (AD) epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AD therapeutics in each of the markets covered.

FAQs

  • In 2023, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in the 8MM.

  • The total prevalent cases of Alzheimer’s disease (AD) will register an AGR of more than 4% during 2023-2033.

  • In 2023, the number of total prevalent cases of Alzheimer’s disease (AD) was higher in women in the 8MM combined.

  • Among the 8MM, Italy had the largest differences in the total prevalent cases of Alzheimer’s disease (AD) in men and women.

What our clients have to say

More Reports

View More Reports